Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) CEO Todd Harris sold 600 shares of Tyra Biosciences stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $24.01, for a total value of $14,406.00. Following the transaction, the chief executive officer now directly owns 1,477,873 shares of the company's stock, valued at approximately $35,483,730.73. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Todd Harris also recently made the following trade(s):
- On Monday, September 23rd, Todd Harris sold 10,092 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.13, for a total value of $243,519.96.
- On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.31, for a total transaction of $138,518.38.
Tyra Biosciences Stock Performance
Shares of NASDAQ:TYRA opened at $23.28 on Thursday. The company's fifty day moving average is $21.47 and its two-hundred day moving average is $18.81. Tyra Biosciences, Inc. has a 1-year low of $10.38 and a 1-year high of $25.14. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -13.86 and a beta of 1.01.
FDA’s hidden signal greenlights biotech winners — 97% of the time
From Weiss Ratings | Ad
The FDA has started to quietly send out a signal …
That has given investors a 97% chance of making money.
Perhaps as soon as 9:30 a.m. tomorrow.
Click here to find out how you can get in before the FDA’s potential signal.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.09. Sell-side analysts expect that Tyra Biosciences, Inc. will post -1.53 EPS for the current fiscal year.
Institutional Trading of Tyra Biosciences
A number of institutional investors have recently made changes to their positions in TYRA. Oppenheimer & Co. Inc. bought a new stake in Tyra Biosciences during the first quarter worth approximately $977,000. Vanguard Group Inc. lifted its position in shares of Tyra Biosciences by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company's stock valued at $14,757,000 after acquiring an additional 140,833 shares during the last quarter. Kynam Capital Management LP bought a new stake in shares of Tyra Biosciences during the 4th quarter worth $4,712,000. Wellington Management Group LLP grew its holdings in shares of Tyra Biosciences by 8.8% in the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company's stock worth $1,419,000 after acquiring an additional 8,324 shares during the last quarter. Finally, HighVista Strategies LLC acquired a new stake in shares of Tyra Biosciences during the second quarter worth $257,000. 84.14% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of brokerages have recently commented on TYRA. Piper Sandler began coverage on Tyra Biosciences in a research report on Thursday, August 15th. They issued an "overweight" rating and a $33.00 price objective for the company. Oppenheimer increased their price objective on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an "outperform" rating in a report on Thursday, September 19th. Wedbush restated an "outperform" rating and issued a $28.00 target price on shares of Tyra Biosciences in a report on Thursday, August 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $23.00 price target on shares of Tyra Biosciences in a research note on Wednesday, July 3rd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $26.40.
Read Our Latest Report on TYRA
Tyra Biosciences Company Profile
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
